Neil Di Spirito
Principal at DiSpirito Law
Presented Tuesday, April 30, 2024
This webinar focused on the concept of FDA actions not originating from inspections but the other reasons why the FDA may initiate Warning Letters and Actions. Most notably, we discussed Voluntary Records Requests, Unapproved Drugs, and devices, Advertising and promotion, OTC Drugs by monograph, import-export violations (customs referrals), improper distributions, etc.
FDA may use evidence of these violations to bring enforcement actions against companies. A company must understand the regulation and the law behind it, know its rights, know when to call legal counsel, and have a detailed plan to avoid and deal with these alleged violations when they occur.
If you have any questions or comments or need help registering, please do not hesitate to contact someone on our team at [email protected].